| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2017 ( Subtotal = $0 ) |
| 2017 | 2015 | NEMUCORE MEDICAL INNOVATIONS, INC. | 33 KIRKLAND CIR | WELLESLEY | MA | 02481-4812 | NORFOLK | USA | R43CA186562 | Modified MIS Production & Process Development for Preclinical & Clinical Studies | 000 | 1 | NIH | 3/1/2017 | $0 |
| 2017 | 2015 | NEMUCORE MEDICAL INNOVATIONS, INC. | 33 KIRKLAND CIR | WELLESLEY | MA | 02481-4812 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 000 | 5 | NIH | 11/8/2016 | $0 |
| 2017 | 2015 | NEMUCORE MEDICAL INNOVATIONS, INC. | 33 KIRKLAND CIR | WELLESLEY | MA | 02481-4812 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 001 | 5 | NIH | 7/17/2017 | $0 |
|
 | Issue Date FY: 2015 ( Subtotal = $748,530 ) |
| 2015 | 2015 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 000 | 5 | NIH | 3/25/2015 | $523,530 |
| 2015 | 2015 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R43CA186562 | Modified MIS Production & Process Development for Preclinical & Clinical Studies | 000 | 1 | NIH | 1/30/2015 | $225,000 |
|
 | Issue Date FY: 2014 ( Subtotal = $890,525 ) |
| 2014 | 2014 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 000 | 4 | NIH | 4/14/2014 | $665,610 |
| 2014 | 2014 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R43CA183416 | Expression System and Process Development for MIS Scale Up | 000 | 1 | NIH | 7/25/2014 | $224,915 |
|
 | Issue Date FY: 2013 ( Subtotal = $884,791 ) |
| 2013 | 2013 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | U43CA162454 | TARGETED DOCETAXEL-NANOCOLLOID FOR THE TREATMENT OF OVARIAN CANCER | 000 | 1 | NIH | 4/26/2013 | $288,302 |
| 2013 | 2013 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 000 | 3 | NIH | 3/7/2013 | $285,553 |
| 2013 | 2013 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 001 | 3 | NIH | 6/28/2013 | $310,936 |
|
 | Issue Date FY: 2012 ( Subtotal = $540,181 ) |
| 2012 | 2012 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 000 | 2 | NIH | 3/29/2012 | $540,181 |
|
 | Issue Date FY: 2011 ( Subtotal = $721,403 ) |
| 2011 | 2011 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R01CA158881 | Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer | 000 | 1 | NIH | 3/28/2011 | $568,797 |
| 2011 | 2011 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R43CA144591 | EGFR-TARGETED NANOEMULSIONS FOR IMAGING AND THERAPY OF OVARIAN CANCER | 000 | 2 | NIH | 9/6/2011 | $152,606 |
|
 | Issue Date FY: 2010 ( Subtotal = $149,855 ) |
| 2010 | 2010 | NEMUCORE MEDICAL INNOVATIONS INC | 33 KIRKLAND CIRCLE | WELLESLEY | MA | 02481 | NORFOLK | USA | R43CA144591 | EGFR-TARGETED NANOEMULSIONS FOR IMAGING AND THERAPY OF OVARIAN CANCER | 000 | 1 | NIH | 9/21/2010 | $149,855 |
|
|